ＭＤＳの病態と治療

DOI

書誌事項

タイトル別名
  • Clinical status of patients with myelodysplastic syndromes and their therapeutic modalities.
  • SYNDROMES AND THEIR THERAPEUTIC MODALITIES

この論文をさがす

抄録

According as percentage of blast cells in bone marrow was less than 5% or not, a total of 27 patients with myelodysplastic syndrome (MDS) except for chronic myelomonocytic leukemia were classified into group AR (11 patients with refractory anemia and 1 with refractory anemia with ring sideroblasts) and group BT (7 patients with refractory anemia with excess of blasts and 8 with refractory anemia with excess of blasts in transformation), and were analyzed for hematological findings and clinical courses in respect to prognostic significance. Although there was no significant difference among peripheral blood counts between group AR and BT, the titer of serum vitamin Bi2 was significantly higher in gro upBT than AR (P<0.01). Although 50 percent survival time was about 16 months in both groups, long survivors (>4 years) were observed exclusively in group AR. Chromosomal abnormalities at presentation were observed in 3 of 12 AR patients (25%), and in 6 of 9 BT patients (67%). Four of 12 AR patients (33%) and 9 of 15 BT patients (60%) progressed to acute leukemia. Among both groups, survival ratio was significantly higher in patients with normal karyotypes at presentation than in patients with abnormal ones at the points of day 475 and day 970 (P<0.05). However, there was no significant difference between patients who progressed to acute leukemia and patients who did not progress to it in respect to survival ratio. Life expectancy did not seem to be influenced by treatment modalities and responses among group BT patients. It is suggested that new therapeutic approaches to MDS patients according to their clinical status and prognoses are in urgent demand.

収録刊行物

  • 医療

    医療 45 (10), 930-933, 1991

    一般社団法人 国立医療学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ